Parkman Healthcare Partners LLC Grows Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Parkman Healthcare Partners LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 765,453 shares of the company's stock after purchasing an additional 10,209 shares during the quarter. Kiniksa Pharmaceuticals comprises approximately 2.0% of Parkman Healthcare Partners LLC's portfolio, making the stock its 16th largest holding. Parkman Healthcare Partners LLC owned about 1.06% of Kiniksa Pharmaceuticals worth $15,141,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. Teacher Retirement System of Texas increased its stake in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after purchasing an additional 719 shares during the period. Martingale Asset Management L P increased its stake in Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock valued at $976,000 after purchasing an additional 900 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after purchasing an additional 1,100 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after purchasing an additional 1,374 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Ross Moat sold 18,259 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the transaction, the insider now directly owns 9,415 shares of the company's stock, valued at approximately $191,030.35. The trade was a 65.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 2,872 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total value of $77,630.16. Following the transaction, the chief executive officer now directly owns 96,674 shares in the company, valued at $2,613,098.22. This trade represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 231,640 shares of company stock valued at $5,669,136 over the last quarter. Company insiders own 54.57% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the subject of several recent research reports. Wedbush reaffirmed an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Jefferies Financial Group boosted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA traded up $0.37 during trading hours on Monday, reaching $26.62. 138,502 shares of the company were exchanged, compared to its average volume of 618,595. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -190.11 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $17.38 and a 52-week high of $28.56. The stock has a 50 day simple moving average of $22.86 and a 200 day simple moving average of $21.34.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue was up 72.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.25) earnings per share. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.